Awards

The Bayer Hemophilia Awards Program demonstrates Bayer's commitment to the bleeding disorders community and to advancing the state of the art of hemophilia care.

 

As Award decisions are taken by the independent Grants Review and Awards Committee and based on an applicant’s merit and eligibility, all decisions are final and not subject to appeal.

 

    Clinical Research Award

    This award will provide funds to undertake a clinical research project in the bleeding disorders field. Focus areas for such projects include, but are not limited to:

     

    • Developing evidence to support international and national management guidelines
    • Role of tailored, individualized FVIII treatment regimens, for example, for maximizing protection in order to achieve active lifestyles
    • Pain management, for example, joint or muscle pain, pain due to chronic hemophilic arthropathy, dental, postoperative pain
    • Patient-reported outcomes: Definition, documentation, and clinical implications
    • Subclinical / microbleeds: definition, documentation and clinical implications
    • Variability of outcomes in hemophilia A subpopulations, including but not limited to, elderly, co-morbid and adolescents
    • Joint health and interventions in patients with moderate/mild hemophilia A
    • Observational data (RWE) on factor utilization and cost-effectiveness
    • Diversity and equity of access (e.g. mild/moderate, carriers, overlooked populations such as HIV positive, Hepatitis B/C)
    • Innovative digital solution (website, mobile app, or software development)

     

    Clinical Research Project awards will provide funding of up to US$75,000 for one year. Up to 15% may be requested as salary support. Up to 20% may be requested as overhead. One award will be granted for the 2022/2023 cycle.

    Basic Research Award

    This award will provide funds to undertake a basic research project in the bleeding disorders field. Focus areas for such projects include, but are not limited to:

     

    • Investigating the role of FVIII in coagulation and outside of coagulation, for example, musculoskeletal, cancer, hypertension, angiogenesis and hematopoietic stem cells
    • Aspects of the molecular biology of vWF structure and function
    • Laboratory research, services, applications and genetic diagnosis of hemophilia
    • Cell and gene therapy, for example, basic science, tropism, transduction efficiency & tolerability
    • Alternative coagulation products
    • Innovative digital solution (website, mobile app, or software development)

     

    Basic Research Project awards will provide funding of up to US$75,000 for one year. Up to 15% may be requested as salary support. Up to 20% may be requested as overhead. One award will be granted for the 2022/2023 cycle.

    Fellowship Project Award

    This award is intended to facilitate the development of clinical and research expertise in the field of hemophilia for applicants who have completed medical training and have an interest in pursuing a career as a hemophilia clinician. The award will support a mentored physician for one year, who will be expected to undertake a research project as well as clinical training.

     

    The criteria by which applications will be judged include:

     

    • Merit of applicant and approach
    • Design and rationale of research project
    • Design and rationale of the proposed clinical training program.
    • Potential for successful development of the applicant as a clinical expert in the treatment of hemophilia
    • Mentor and learning environment.
    • Commitment of applicant and mentor to hemophilia

     

    Fellowship Project awards will provide funding of up to US$80,000 for one year. Salary support is anticipated; there is no cap but the Committee will be looking for remuneration to be commensurate with institutional norms. Up to 20% may be requested as overhead. Up to one award will be granted for the 2022/2023 cycle.

    Patient Engagement Award

    This award will provide funds to support efforts in the field of patient engagement, education and advocacy within hemophilia. Particular focus on innovative digital solutions (website, mobile app, or software development) is encouraged.It recognizes the essential role of nurses, allied healthcare professionals and caregivers in the care of patients with hemophilia.

     

    The criteria by which applications will be judged include:

     

    • Clarity of rationale and objectives
    • Importance and potential impact of project
    • Plans for dissemination of project findings

     

    The Patient Engagement Award will provide funding of up to US$25,000 for one year. Up to 15% may be requested as salary support. Up to 20% may be requested as overhead. Up to 1 award will be granted for for the 2022/2023 cycle.

    Eligibility

    CLINICAL AND BASIC RESEARCH AWARDS

     

    Any individual affiliated with a facility that carries out research in inherited bleeding disorders, or provides care to patients with these disorders, may make a request for these awards. Such facilities may include medical universities, hospitals, treatment centers, blood centers and laboratories.

     

    FELLOWSHIP PROJECT AWARD

     

    The applicant will be affiliated with a facility that carries out research in inherited bleeding disorders or provides care to patients with these disorders. Such facilities may include medical universities, hospitals, treatment centers, blood centers and laboratories. The applicant should have earned his/her medical degree within the previous eight years. The applicant may not have received previous funding from this award category.

    Want to apply for the Bayer Hemophilia Awards Program?

    Submit a Proposal

    ©2021 Bayer.

    All rights reserved. PP-PF-HEM-ALL-0444-1 

    Last update: 02/08/2021